



September 4, 2020

Veracyte to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 4, 2020-- [Veracyte, Inc.](#) (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to participate in two upcoming virtual investor conferences:

- Baird's 2020 Global Healthcare Conference
Presentation on Wednesday, September 9, 2020, at 1:25 p.m. ET
- Morgan Stanley 18th Annual Global Healthcare Conference
Fireside chat on Monday, September 14, 2020; 11:15 a.m. ET

Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at <http://investor.veracyte.com/events-presentations>. Replays of the webcasts will be available for 90 days following the conclusion of each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200904005150/en/): <https://www.businesswire.com/news/home/20200904005150/en/>

Investors and Media Contact:

Tracy Morris
tracy.morris@veracyte.com
650-380-4413

Source: Veracyte, Inc.